Suchergebnisse - "Balser, Sigrid"

PubPharm (17)

1

Phase 3 Trial of BI 695502 Plus Chemotherapy Versus Bevacizumab Reference Product Plus Chemotherapy in Patients With Advanced Nonsquamous NSCLC

enthalten in: JTO clinical and research reports | 2022

von Kim, E. | Balser, S. | Rohr, K. | +3

2

Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD) : a multicentre, randomised, double-blind, phase 3 trial

enthalten in: The lancet. Gastroenterology & hepatology | 2021

von Hanauer, S. | Liedert, B. | Balser, S. | +3

CommentIn: Lancet Gastroenterol Hepatol. 2021 Oct;6(10):775-776. - PMID 34388361

3

Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis : results from the randomized Phase III VOLTAIRE-PSO study

enthalten in: Expert opinion on biological therapy | 2021

von Menter, A. | Arenberger, P. | Balser, S. | +7

4

Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human Epoetin Alfa and the Biosimilar HX575

enthalten in: Journal of clinical pharmacology | 2012

von Yan, X. | Lowe, P. | Fink, M. | +3

5

Population Pharmacokinetic and Pharmacodynamic Model-Based Comparability Assessment of a Recombinant Human Epoetin Alfa and the Biosimilar HX575

enthalten in: The journal of clinical pharmacology | 2012

von Yan, X. | Lowe, P. | Fink, M. | +3

6

Effect of switching recombinant human growth hormone: Comparative analysis of phase 3 clinical data

enthalten in: Biologics in therapy | 2011

von Romer, T. | Zabransky, M. | Walczak, M. | +2

7

Effect of switching recombinant human growth hormone : Comparative analysis of phase 3 clinical data

enthalten in: Biologics in therapy | 2011

von Romer, T. | Zabransky, M. | Walczak, M. | +2

8

Population modeling of filgrastim PK-PD in healthy adults following intravenous and subcutaneous administrations

enthalten in: Journal of clinical pharmacology | 2010

von Krzyzanski, W. | Wiczling, P. | Lowe, P. | +4

9

Population Modeling of Filgrastim PK‐PD in Healthy Adults Following Intravenous and Subcutaneous Administrations

enthalten in: The journal of clinical pharmacology | 2010

von Krzyzanski, W. | Wiczling, P. | Lowe, P. | +4

10

Bioequivalence between novel ready-to-use liquid formulations of the recombinant human GH Omnitrope and the original lyophilized formulations for reconstitution of Omnitrope and Genotropin

enthalten in: European journal of endocrinology | 2010

von Fuhr, U. | Tuculanu, D. | Berghout, A. | +3